<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">Pharmacodynamic and pharmacokinetic properties of peptidomimetic M
 <sup>pro</sup> inhibitors like 
 <bold>2</bold>, 
 <bold>3</bold>, 
 <bold>5</bold> or 
 <bold>6</bold> already point into the right direction.
 <xref rid="b0295" ref-type="bibr">59</xref>, 
 <xref rid="b0455" ref-type="bibr">91</xref> Although peptide-aldehydes have entered clinical trials before (e.g. efegatran),
 <xref rid="b0515" ref-type="bibr">103</xref>, 
 <xref rid="b0520" ref-type="bibr">104</xref>
 <bold>5</bold> and 
 <bold>6</bold> are likely to face challenges during further drug development. The α-ketoamide in 
 <bold>1</bold>–
 <bold>3</bold> or Michael acceptor in 
 <bold>4</bold> are covalent modifiers with precedents in approved drugs (e.g. telaprevir or afatinib).
 <xref rid="b0310" ref-type="bibr">62</xref>, 
 <xref rid="b0525" ref-type="bibr">105</xref> Potential problems associated with limited drug-likeness of peptidomimetics could be circumvented by pursuing alternative small molecules, which might, for example, be accessible from fragment-based drug discovery campaigns.
 <xref rid="b0505" ref-type="bibr">101</xref>, 
 <xref rid="b0530" ref-type="bibr">106</xref>
</p>
